Evidence map›Paper›PMID 42301000›Full record

ArticleCardiovascular therapeutics2026

Lycorine Attenuates Cardiac Fibrosis Through the Regulation of PYK2 Expression and Activity.

Xiuxiu Gao, Ying Zhang, Dongzhe Li, Yufei Chen, Weimiao Qi, Shufang Cui, Chen Wang, Zhong Wang, Quanyi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiuxiu GaoDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0009-0005-7034-4049
Ying ZhangDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0009-0003-8065-9816
Dongzhe LiDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0009-0000-6558-0702
Yufei ChenDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0009-0004-7147-9255
Weimiao QiDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0009-0001-8645-1931
Shufang CuiDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0000-0003-3467-1825
Chen WangDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0000-0002-4948-0469
Zhong WangJiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany Jiangsu Province and Chinese Academy of Sciences (Nanjing Botanical Garden Mem. Sun Yat-Sen), Nanjing, Jiangsu, China.ORCID https://orcid.org/0000-0002-0498-0435
Quanyi WangDepartment of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, China, cpu.edu.cn.ORCID https://orcid.org/0000-0001-6773-0057

Funding

Forestry Science, Technology Popularization Demonstration Project of the Central Finance Su (2024) TG06Jiangsu Provincial Crop Germplasm Resource Bank JS-ZW-K04National Natural Science Foundation for Youth 82300337Natural Science Foundation of Jiangsu Province BK20253030 BK20220152
6 · The paper itself

Abstract

Lycorine (LYC), the most abundant monomeric compound from Lycoris radiata bulbs, possesses a range of biological activities, including antipulmonary fibrosis and cardioprotective effects. However, its role in regulating pathological cardiac remodeling, particularly in cardiac fibrosis, remains unclear. In this study, we used transforming growth factor-β1 (TGF-β1) to stimulate NIH/3T3 cells and primary rat cardiac fibroblasts, which were in vitro models of pathological fibroblast activation, and established a mouse model of cardiac fibrosis via intraperitoneal injection of doxorubicin (DOX). The effects of LYC on TGF-β1-induced fibroblast activation and migration were assessed using Western blotting, quantitative PCR, scratch assays, and EdU staining. Cardiac damage and fibrosis were evaluated in vivo by echocardiography, enzyme-linked immunosorbent assay (ELISA), and Masson's trichrome staining. Through transcriptomic sequencing and bioinformatic analyses, proline-rich tyrosine kinase 2 (PYK2) was identified as a potential target of LYC. This finding was further validated using siPYK2 and the PYK2 inhibitor PF4618433 in TGF-β1-induced NIH/3T3 cells. Our results demonstrated that LYC effectively suppressed fibroblast activation, proliferation, and migration. In addition, LYC significantly ameliorated cardiac dysfunction and reduced collagen deposition in myocardial tissues, thereby attenuating the progression of cardiac fibrosis. Mechanistically, these effects were attributed to the regulation of PYK2 expression and activity by LYC. This study provides a scientific basis for understanding the mechanism of LYC in improving cardiac fibrosis and highlights PYK2 as a potential therapeutic target for the treatment of cardiac fibrosis.

Indexed as

Amaryllidaceae AlkaloidsAntifibrotic AgentsCardiomyopathiesFibroblastsFocal Adhesion Kinase 2MyocardiumPhenanthridinesVentricular RemodelingAnimalsCell MovementCell ProliferationDisease Models, AnimalDoxorubicinFibrosisMaleMiceAmaryllidaceae AlkaloidsAntifibrotic AgentsDoxorubicinFocal Adhesion Kinase 2lycorinePhenanthridinesTransforming Growth Factor beta1cardiac fibrosisERK1/2lycorinePYK2

Identifiers

PMID42301000
PMCPMC13270775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.